Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.

Emory University School of Medicine, US, has commenced subject enrolment for BioCardia’s Phase III CardiAMP HF II trial.

Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

With trial costs rising over the past decade and concerns they’ll keep climbing, companies are seeking ways to manage ...